These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31969034)

  • 1. The safety of carbamylated monomeric allergoids for sublingual immunotherapy. Data from a pharmacovigilance study.
    Compalati E; Incorvaia C; Urbano S; Strada P; Frati F
    Immunotherapy; 2020 Feb; 12(3):195-202. PubMed ID: 31969034
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of subcutaneous and sublingual immunotherapy with allergoids in children: a real-life pharmacovigilance study.
    Frati F; Beni N; Marastoni L; Compalati E; Ciprandi G
    Immunotherapy; 2024 Jan; 16(1):43-53. PubMed ID: 38018469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of subcutaneous immunotherapy with carbamylated allergoids based on data from a pharmacovigilance database.
    Franco F; Cristoforo I; Francesca S; Arianna P; Laura M; Carlo C; Simonetta M; Enrico C
    Immunotherapy; 2022 Oct; 14(15):1219-1224. PubMed ID: 36046924
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of allergoid immunotherapy: is cat allergy a suitable target?
    Nguyen NT; Raskopf E; Shah-Hosseini K; Zadoyan G; Mösges R
    Immunotherapy; 2016; 8(3):331-49. PubMed ID: 26860435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients.
    Hüser C; Dieterich P; Singh J; Shah-Hosseini K; Allekotte S; Lehmacher W; Compalati E; Mösges R
    Allergy; 2017 Jan; 72(1):77-84. PubMed ID: 27068870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of allergoids in allergen immunotherapy: from injective to sublingual route.
    Compalati E; Incorvaia C; Cavaliere C; Masieri S; Gargiulo A; Mistrello G; Frati F
    Eur Ann Allergy Clin Immunol; 2020 Sep; 52(5):195-204. PubMed ID: 32338477
    [No Abstract]   [Full Text] [Related]  

  • 7. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
    Mösges R; Ritter B; Kayoko G; Allekotte S
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients.
    Mösges R; Rohdenburg C; Eichel A; Zadoyan G; Kasche EM; Shah-Hosseini K; Lehmacher W; Schmalz P; Compalati E
    Immunotherapy; 2017 Nov; 9(15):1225-1238. PubMed ID: 29130797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?
    Cavaliere C; Incorvaia C; Begvarfaj E; Orlando MP; Turchetta R; Musacchio A; Ralli M; Ciofalo A; Greco A; de Vincentiis M; Masieri S
    Expert Opin Drug Saf; 2021 Mar; 20(3):259-264. PubMed ID: 33427529
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules.
    Passali D; Mösges R; Passali GC; Passali FM; Ayoko G; Bellussi L
    Acta Otorhinolaryngol Ital; 2010 Jun; 30(3):131-7. PubMed ID: 20948588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.
    Bernstein DI; Bardelas JA; Svanholm Fogh B; Kaur A; Li Z; Nolte H
    Postgrad Med; 2017 Aug; 129(6):590-597. PubMed ID: 28326906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of Sublingual Immunotherapy Tablets and Management of Potential Adverse Effects: Austrian, German, and Swiss Expert Recommendations.
    Sturm GJ; Vogelberg C; Marchon M; Horn A; Vitzthum HG; Memar-Baschi MP; Kleine-Tebbe J
    Clin Ther; 2019 Sep; 41(9):1880-1888. PubMed ID: 31353131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of sublingual immunotherapy in children.
    Frati F; Ridolo E; Fuiano N; Barberi S; Dell'Albani I; Landi M; Ricciardi L; Scala G; Incorvaia C
    Expert Opin Drug Saf; 2014 Jul; 13(7):947-53. PubMed ID: 24821477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.
    Nieto A; Mazón Á; Nieto M; Ibáñez E; Jang DT; Calaforra S; Alba P; Pérez-Francés C; Llusar R; Montoro J; de Mateo A; Alamar R; El-Qutob D; Fernández J; Moral L; Toral T; Antón M; Andreu C; Ferrer Á; Flores IM; Cerdá N; Del Pozo S; Caballero R; Subiza JL; Casanovas M
    Allergy; 2022 Oct; 77(10):3096-3107. PubMed ID: 35570712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States.
    Epstein TG; Calabria C; Cox LS; Dreborg S
    J Allergy Clin Immunol Pract; 2017; 5(1):34-40.e2. PubMed ID: 27815065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice.
    Soria I; López-Relaño J; Viñuela M; Tudela JI; Angelina A; Benito-Villalvilla C; Díez-Rivero CM; Cases B; Manzano AI; Fernández-Caldas E; Casanovas M; Palomares O; Subiza JL
    Allergy; 2018 Apr; 73(4):875-884. PubMed ID: 29319882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of patients for sublingual versus subcutaneous immunotherapy.
    Larenas Linnemann DE; Blaiss MS
    Immunotherapy; 2014; 6(7):871-84. PubMed ID: 25290418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for Safety of Allergen-Specific Sublingual Immunotherapy in Children with Allergic Rhinitis.
    Liu W; Zeng Q; Yan S; Sun C; Tang Y; Luo R
    Int Arch Allergy Immunol; 2020; 181(12):934-940. PubMed ID: 32937623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated Dose Escalation with Three Injections of an Aluminum Hydroxide-Adsorbed Allergoid Preparation of Six Grasses Is Safe for Patients with Moderate to Severe Allergic Rhinitis.
    Kopp MV; Bovermann X; Klimek L
    Int Arch Allergy Immunol; 2020; 181(2):94-102. PubMed ID: 31865326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.